Sanofi
SNY
587 hedge funds and large institutions have $9.61B invested in Sanofi in 2022 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 192 increasing their positions, 209 reducing their positions, and 125 closing their positions.
212% more call options, than puts
Call options by funds: $234M | Put options by funds: $74.8M
8% more funds holding in top 10
Funds holding in top 10: 13 → 14 (+1)
0.3% less ownership
Funds ownership: 20.42% → 20.12% (-0.3%)
8% less repeat investments, than reductions
Existing positions increased: 192 | Existing positions reduced: 209
10% less funds holding
Funds holding: 655 → 587 (-68)
26% less capital invested
Capital invested by funds: $12.9B → $9.61B (-$3.33B)
48% less first-time investments, than exits
New positions opened: 65 | Existing positions closed: 125
Top Buyers
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$259M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$156M |
| 3 |
JP Morgan Chase
New York
|
+$114M |
| 4 |
Millennium Management
New York
|
+$80.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$62.9M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$220M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
-$162M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$115M |
| 4 |
BlackRock
New York
|
-$114M |
| 5 |
Lazard Asset Management
New York
|
-$78.4M |
SNY Hedge Fund Activity: Q3 2022 in Review
587 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q3 2022, worth a combined $9.61B — down 26% from $12.9B a quarter earlier.
Sellers outnumbered buyers: 125 funds closed out of SNY and 65 opened new positions — a net loss of 60 holders — while 209 trimmed existing stakes and 192 added.
The largest buyer was Boston Partners, adding an estimated $259M. The largest seller was T. Rowe Price Associates, cutting an estimated $220M.
- 587 institutional investors held Sanofi (SNY) as of Q3 2022, down from 655 in Q2 2022.
- Funds reported $9.61B of Sanofi stock for Q3 2022, down 26% quarter-over-quarter.
- 65 funds opened new Sanofi positions in Q3 2022 and 125 closed out, a net change of -60 holders.
- The largest Sanofi buyer in Q3 2022 was Boston Partners, an estimated $259M added.
- The largest Sanofi seller in Q3 2022 was T. Rowe Price Associates, an estimated $220M sold.
Based on aggregated 13F filings for Q3 2022.